NASDAQ:VIVO - Meridian Bioscience Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$16.82 +0.20 (+1.20 %)
(As of 01/18/2019 04:00 PM ET)
Previous Close$16.82
Today's Range$16.57 - $16.95
52-Week Range$13.53 - $19.84
Volume386,427 shs
Average Volume337,725 shs
Market Capitalization$704.74 million
P/E Ratio22.73
Dividend Yield3.01%
Beta0.6
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the Alethia brand; rapid immunoassays, a single-use immunoassays under the ImmunoCard and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the PREMIER brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand. This segment's products are primarily used in the detection of infectious diseases caused by various bacteria, viruses, parasites, and pathogens. Its products consists of gastrointestinal assays, including tests for C. difficile, Enterohemorrhagic E. coli, Campylobacter jejuni, H. pylori, Cryptosporidium, giardia lamblia, and calprotectin; respiratory illness assays, such as tests for Group A Streptococcus, Influenza, M. pneumoniae, Bordetella pertussis, and respiratory syncytial virus; blood chemistry assays; and tests for Group B Streptococcus, Chlamydia trachomatis, Neisseria gonorrhea, Herpes Simplex Virus Type 1 and Type 2, and Malaria. This segment sells its products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. Meridian Bioscience, Inc. was founded in 1976 and is headquartered in Cincinnati, Ohio.

Receive VIVO News and Ratings via Email

Sign-up to receive the latest news and ratings for VIVO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:VIVO
CUSIP58958410
Phone513-271-3700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$213.57 million
Cash Flow$0.9639 per share
Book Value$4.14 per share

Profitability

Net Income$23.84 million

Miscellaneous

Employees585
Market Cap$704.74 million
OptionableOptionable

Meridian Bioscience (NASDAQ:VIVO) Frequently Asked Questions

What is Meridian Bioscience's stock symbol?

Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO."

How often does Meridian Bioscience pay dividends? What is the dividend yield for Meridian Bioscience?

Meridian Bioscience announced a quarterly dividend on Friday, November 9th. Stockholders of record on Monday, November 19th will be given a dividend of $0.125 per share on Friday, November 30th. This represents a $0.50 dividend on an annualized basis and a dividend yield of 2.97%. The ex-dividend date of this dividend is Friday, November 16th. View Meridian Bioscience's Dividend History.

How were Meridian Bioscience's earnings last quarter?

Meridian Bioscience, Inc. (NASDAQ:VIVO) released its earnings results on Thursday, November, 8th. The company reported $0.20 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.16 by $0.04. The company had revenue of $213.60 million for the quarter, compared to analysts' expectations of $51.11 million. Meridian Bioscience had a net margin of 11.17% and a return on equity of 18.18%. The company's revenue for the quarter was up 6.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.15 EPS. View Meridian Bioscience's Earnings History.

When is Meridian Bioscience's next earnings date?

Meridian Bioscience is scheduled to release their next quarterly earnings announcement on Thursday, January 24th 2019. View Earnings Estimates for Meridian Bioscience.

How can I listen to Meridian Bioscience's earnings call?

Meridian Bioscience will be holding an earnings conference call on Thursday, January 24th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8664435802.

What guidance has Meridian Bioscience issued on next quarter's earnings?

Meridian Bioscience issued an update on its FY 2019 earnings guidance on Thursday, November, 8th. The company provided earnings per share guidance of $0.74-0.76 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.77. The company issued revenue guidance of $217.842-222.114 million, compared to the consensus revenue estimate of $217.65 million.Meridian Bioscience also updated its guidance to EPS.

What price target have analysts set for VIVO?

1 brokers have issued 1-year target prices for Meridian Bioscience's stock. Their forecasts range from $16.00 to $16.00. On average, they anticipate Meridian Bioscience's stock price to reach $16.00 in the next year. This suggests that the stock has a possible downside of 4.9%. View Analyst Price Targets for Meridian Bioscience.

What is the consensus analysts' recommendation for Meridian Bioscience?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Meridian Bioscience in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Meridian Bioscience.

Has Meridian Bioscience been receiving favorable news coverage?

News coverage about VIVO stock has been trending somewhat positive this week, InfoTrie reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Meridian Bioscience earned a daily sentiment score of 0.9 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the company's share price in the next several days.

Who are some of Meridian Bioscience's key competitors?

Who are Meridian Bioscience's key executives?

Meridian Bioscience's management team includes the folowing people:
  • Mr. John P. Kenny, CEO, Exec. VP of Diagnostics Bus. Unit & Director (Age 51)
  • Ms. Melissa A. Lueke, Exec. VP, CFO, Principal Accounting Officer & Sec. (Age 56)
  • Mr. Lawrence J. Baldini, Exec. VP of Global Operations (Age 60)
  • Ms. Susan D. Rolih, Consultant (Age 70)
  • Mr. Eric S. Rasmussen, Exec. VP of Corp. Devel. (Age 52)

Who are Meridian Bioscience's major shareholders?

Meridian Bioscience's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Cardinal Capital Management (0.07%), Louisiana State Employees Retirement System (0.04%) and Advisors Preferred LLC (0.01%). Company insiders that own Meridian Bioscience stock include John A Kraeutler, John Mccune Jr Rice, John Mcilwraith, Lawrence Baldini and Melissa Lueke. View Institutional Ownership Trends for Meridian Bioscience.

Which major investors are selling Meridian Bioscience stock?

VIVO stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System. View Insider Buying and Selling for Meridian Bioscience.

Which major investors are buying Meridian Bioscience stock?

VIVO stock was acquired by a variety of institutional investors in the last quarter, including Advisors Preferred LLC and Cardinal Capital Management. Company insiders that have bought Meridian Bioscience stock in the last two years include John A Kraeutler, John Mccune Jr Rice, John Mcilwraith, Lawrence Baldini and Melissa Lueke. View Insider Buying and Selling for Meridian Bioscience.

How do I buy shares of Meridian Bioscience?

Shares of VIVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Meridian Bioscience's stock price today?

One share of VIVO stock can currently be purchased for approximately $16.82.

How big of a company is Meridian Bioscience?

Meridian Bioscience has a market capitalization of $704.74 million and generates $213.57 million in revenue each year. The company earns $23.84 million in net income (profit) each year or $0.74 on an earnings per share basis. Meridian Bioscience employs 585 workers across the globe.

What is Meridian Bioscience's official website?

The official website for Meridian Bioscience is http://www.meridianbioscience.com.

How can I contact Meridian Bioscience?

Meridian Bioscience's mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The company can be reached via phone at 513-271-3700.


MarketBeat Community Rating for Meridian Bioscience (NASDAQ VIVO)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  214 (Vote Outperform)
Underperform Votes:  334 (Vote Underperform)
Total Votes:  548
MarketBeat's community ratings are surveys of what our community members think about Meridian Bioscience and other stocks. Vote "Outperform" if you believe VIVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VIVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel